Danske Bank has upgraded its sales forecast for Novo Nordisk’s second quarter, citing robust demand for the company’s oral weight-loss treatment, Wegovy.
The investment bank’s latest analysis suggests that the pill’s commercial performance is outpacing earlier estimates, prompting a more optimistic view of the upcoming quarterly results.
The revision underscores the accelerating shift in Novo Nordisk’s growth engine from injectable formulations to oral alternatives.
As the pharmaceutical giant expands its obesity portfolio, the Wegovy pill is emerging as a critical driver of near-term revenue, reducing reliance on supply-constrained injectables and broadening patient access.
This positive outlook aligns with recent bullish sentiment from other market participants.
Jefferies recently raised its price target for Novo Nordisk shares to DKK 285, up from DKK 270, reflecting confidence in the company’s near-term prospects.